GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Propanc Biopharma Inc (OTCPK:PPCB) » Definitions » Total Payout Ratio

Propanc Biopharma (Propanc Biopharma) Total Payout Ratio : 0.00 (As of May. 23, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Propanc Biopharma Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Propanc Biopharma's current Total Payout Ratio is 0.00.


Propanc Biopharma Total Payout Ratio Historical Data

The historical data trend for Propanc Biopharma's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Propanc Biopharma Total Payout Ratio Chart

Propanc Biopharma Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Total Payout Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.19 0.10 - 0.04 0.01

Propanc Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Propanc Biopharma's Total Payout Ratio

For the Biotechnology subindustry, Propanc Biopharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Propanc Biopharma's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Propanc Biopharma's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Propanc Biopharma's Total Payout Ratio falls into.



Propanc Biopharma Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Propanc Biopharma's Total Payout Ratio for the fiscal year that ended in Jun. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0.025 + 0) / -2.661
=0.01

Propanc Biopharma's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -0.527
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Propanc Biopharma Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Propanc Biopharma's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Propanc Biopharma (Propanc Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Executives
Josef Zelinger director 59 SEYMOUR ROAD, ELSTERNWICK C3 3185
Carlo M Campiciano officer: CFO & Secretary C/O. PROPANC BIOPHARMA,INC., 302, 6 BUTLER STREET, CAMBERWELL C3 3124
Julian Norman Kenyon director BEECHWOOD, EMBLEY LANE, EAST WELLOW, ROMSEY HAMPSHIRE X0 SO516DN
James Andrew Nathanielsz director, officer: CEO, CFO, Secretary, Treasurer 1/76 SUMMERHILL ROAD, GLEN IRIS, VICTORIA C3 3146